GSK3B and neoplasm: In breast and tumor tissues, delphinidin treatment also inhibits the expression of β-catenin, p-GSK-3β, c-Myc, cyclin-D1, and MMP-7 and upregulates miR-34a, a master regulator of tumor suppression.